Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Qihui (Jim) Zhai

Qihui "Jim" Zhai, M.D., F.C.A.P.

 

Qihui Jim Zhai, M.D., F.C.A.P.

Qihui "Jim" Zhai, M.D., F.C.A.P.

Assistant Member
The Methodist Hospital Research Institute
Medical Director, Immunohistochemistry Laboratory
The Methodist Hospital
Assistant Professor, Department of Pathology and Laboratory Medicine
Weill Cornell Medical College of Cornell University

E-mail: qzhai@houstonmethodist.org
Phone: 713-441-6409
Fax: 713-793-1603


Education

M.D.   Shandong Medical University, Shandong, P.R. China
M.S.c.   Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, P.R. China

Postdoctoral Training

Anatomic pathology residency, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN
Surgical Pathology Fellowship, Department of Pathology, MD Anderson Cancer Center, Houston, TX

 

Biography

After completing his MSc in Beijing, Dr. Zhai accepted a postdoctoral research fellowship in the Department of Neurology at the Medical College of Ohio in Toledo, Ohio. He was promoted to assistant professor and associate director of the Cerebrovascular Disease Laboratory in 1995. He left Ohio in 1998 to pursue his residency and fellowship training in pathology, first at the Mayo Clinic and then at MD Anderson Cancer Center. While in residency at Mayo, he investigated the role of NMDA receptor activation in neuronal plasticity in response to brain ischemia. At MD Anderson, he researched possible mechanisms of herceptin resistance in HER2/neu-positive breast cancer patients. In 2003, he joined the faculty at Baylor College of Medicine as an assistant professor in the Department of Pathology and accepted the position at the Methodist Hospital as director of the Immunohistochemistry Laboratory in 2005. He is an active physician-scientist and has had uninterrupted funding from both federal and private sources since 1998.

Description of Research

Dr. Zhai´s research focuses primarily on testing the efficacy of different biomarkers in diagnosis and therapeutic responses.

Major Areas of Research

Pathology, oncology, renal cell neoplasm, pancreatic cancer

Recent Publications

Zhang Y, Feurino LW, Zhai Q, Wang H, Fisher WE, Chen C, Yao Q, Li M. (2007) Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther 7(3) Epub ahead of print.

Zhai QJ, Black J, Ayala AG, Ro JY. (2007) Histologic variants of infiltrating urothelial carcinoma. Arch Pathol Lab Med 131:1244-56.

Ozcan A, Shen SS, Zhai QJ, Truong LD. (2007) Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am J Clin Pathol 128:245-54.

Shen SS, Ro JY, Tamboli P, Truong LD, Zhai Q, Jung SJ, Tibbs RG, Ordonez NG, Ayala AG. (2007) Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol 11:13-21.

Li M, Feurino LW, Li F, Wang H, Zhai Q, Fisher WE, Chen C, Yao Q. (2006) Thymosinalpha1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells. Cancer Lett 248:58-67.

Li M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE, Chen C, Yao Q. (2006) Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 106:2284-94.